IRIS
GRAGNANO, Felice
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.983
AS - Asia 3.551
NA - Nord America 2.529
SA - Sud America 679
AF - Africa 63
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 4
Totale 10.814
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.463
RU - Federazione Russa 2.078
SG - Singapore 1.328
CN - Cina 875
IE - Irlanda 771
HK - Hong Kong 631
BR - Brasile 578
IT - Italia 332
VN - Vietnam 207
GB - Regno Unito 203
KR - Corea 201
DE - Germania 182
IN - India 131
FR - Francia 90
UA - Ucraina 54
GR - Grecia 53
AR - Argentina 46
FI - Finlandia 43
AT - Austria 42
SE - Svezia 38
JP - Giappone 29
CA - Canada 28
MX - Messico 27
BD - Bangladesh 26
BE - Belgio 22
TR - Turchia 22
ID - Indonesia 19
CO - Colombia 18
NL - Olanda 17
IQ - Iraq 16
EG - Egitto 14
ES - Italia 13
PK - Pakistan 13
ZA - Sudafrica 13
MA - Marocco 12
EC - Ecuador 11
KE - Kenya 11
PL - Polonia 10
UZ - Uzbekistan 8
LT - Lituania 7
VE - Venezuela 7
CL - Cile 5
HN - Honduras 5
JO - Giordania 5
SA - Arabia Saudita 5
AE - Emirati Arabi Uniti 4
AU - Australia 4
CZ - Repubblica Ceca 4
IL - Israele 4
NO - Norvegia 4
PE - Perù 4
PY - Paraguay 4
RS - Serbia 4
TN - Tunisia 4
TW - Taiwan 4
UY - Uruguay 4
EU - Europa 3
IR - Iran 3
MD - Moldavia 3
NP - Nepal 3
AM - Armenia 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
KZ - Kazakistan 2
MY - Malesia 2
TH - Thailandia 2
AL - Albania 1
AN - Antille olandesi 1
AO - Angola 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BW - Botswana 1
CH - Svizzera 1
CR - Costa Rica 1
CY - Cipro 1
DK - Danimarca 1
EE - Estonia 1
ET - Etiopia 1
GE - Georgia 1
GH - Ghana 1
GY - Guiana 1
HR - Croazia 1
IS - Islanda 1
JM - Giamaica 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
LV - Lettonia 1
MK - Macedonia 1
MU - Mauritius 1
NG - Nigeria 1
OM - Oman 1
PA - Panama 1
PT - Portogallo 1
PW - Palau 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 10.811
Salva come PNG Salva come JPEG
Città #
Dublin 757
Moscow 694
Santa Clara 656
Hong Kong 628
Singapore 461
Chandler 359
Hefei 246
Seoul 197
Beijing 125
The Dalles 102
Jacksonville 100
New York 96
Princeton 94
Roxbury 94
Bengaluru 90
Ho Chi Minh City 77
Ashburn 73
Dallas 67
Naples 60
São Paulo 51
Cambridge 49
Medford 48
Nuremberg 47
Bremen 44
Hanoi 42
Falkenstein 35
Des Moines 32
Boardman 29
Los Angeles 28
Ann Arbor 26
Caserta 26
Wilmington 24
Brussels 22
Rio de Janeiro 19
Aversa 18
Lappeenranta 18
Helsinki 15
Hyderabad 15
Nanjing 15
Belo Horizonte 14
Munich 13
Brooklyn 11
Dhaka 11
Guangzhou 11
Houston 11
Vienna 11
Boston 10
Brasília 10
Curitiba 10
Ercolano 10
Napoli 10
Porto Alegre 10
Rome 10
Amsterdam 9
Da Nang 9
Jinan 9
Milan 9
Montreal 9
Nairobi 9
Salvador 9
Bogotá 8
Campinas 8
Columbus 8
Johannesburg 8
London 8
Mexico City 8
Norwalk 8
San Francisco 8
Sivas 8
Tashkent 8
Frankfurt am Main 7
Haiphong 7
Hangzhou 7
Stockholm 7
Turku 7
Cairo 6
Changsha 6
Phoenix 6
San Giovanni In Fiore 6
Thái Bình 6
Toronto 6
Woodbridge 6
Zhengzhou 6
Afragola 5
Amman 5
Baghdad 5
Bauru 5
Casablanca 5
Guarulhos 5
Hải Dương 5
Juiz de Fora 5
Las Vegas 5
Nova Iguaçu 5
Santo André 5
Shanghai 5
Shenzhen 5
Turin 5
Atlanta 4
Biên Hòa 4
Blumenau 4
Totale 6.039
Salva come PNG Salva come JPEG
Nome #
Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: the prospective AIRE Study 148
MicroRNA-33 and SIRT1 influence the coronary thrombus burden in hyperglycemic STEMI patients 124
Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience 116
Adherence to PCSK9 inhibitors in high cardiovascular risk patients in real-world setting: results from a single-center experience and comparison with statin therapy 108
Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease 107
Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry 106
Access-Site Crossover in Patients With Acute Coronary Syndrome Undergoing Invasive Management 105
Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition 103
Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: the emerging role of the Cardiomyopathy Team 100
Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry 97
Cardiorenal Impact of SGLT-2 Inhibitors: A Conceptual Revolution in The Management of Type 2 Diabetes, Heart Failure and Chronic Kidney Disease 96
Natural history of left ventricular hypertrophy in infants of diabetic mothers 95
Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: A contemporary reappraisal 93
Acute kidney injury in patients with acute coronary syndrome undergoing invasive management treated with bivalirudin vs. unfractionated heparin: insights from the MATRIX trial 93
New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia 93
null 93
[Device therapy in chronic heart failure: a case of hypertrophic cardiomyopathy treated with cardiac contractility modulation therapy] 92
[The COMPASS study] 92
Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience 92
A call for action in bleeding prevention 90
Coronary Physiology Assessment for the Diagnosis and Treatment of Coronary Artery Disease 89
[Evaluation and percutaneous treatment of severely calcified coronary lesions] 87
Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry 87
Medical treatment of patients with hypertrophic cardiomyopathy: An overview of current and emerging therapy 84
Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry) 84
How do cardiologists select patients for dual antiplatelet therapy continuation beyond 1 year after a myocardial infarction? Insights from the EYESHOT Post-MI Study 83
Alcohol Septal Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy: A Contemporary Perspective 82
Anti-inflammatory therapies for cardiovascular diseases: novel evidence, clinical implications, and future perspectives 81
Sodium-Glucose Co-Transporters Family: Current Evidence, Clinical Applications and Perspectives 79
Are we ready for a gender-specific approach in interventional cardiology? 79
Mandatory reporting of coronary artery calcifications incidentally noted on chest multi-detector computed tomography: a multicentre experience 78
Thrombus aspiration in hyperglycemic ST-elevation myocardial infarction (STEMI) patients: Clinical outcomes at 1-year follow-up 78
Early-onset MINOCA: Prognostic implications and considerations for practice 78
A Prospective Study to Evaluate the Effectiveness of Edoxaban for the Resolution of Left Atrial Thrombosis in Patients with Atrial Fibrillation 77
Functional assessment of coronary stenosis: an overview of available techniques. Is quantitative flow ratio a step to the future? 76
Antithrombotic Therapy Optimization in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention 75
Von Willebrand Factor and cardiovascular disease: from a biochemical marker to an attractive therapeutic target 75
Dietary thiols: A potential supporting strategy against oxidative stress in heart failure and muscular damage during sports activity 74
Anticoagulation After Primary PCI: The Land of Promises and Uncertainty 74
Antithrombotic therapy in patients with atrial high-rate episodes (AHREs): Current evidence and open questions 73
[Debate on antiplatelet monotherapy: P2Y12 inhibitor monotherapy in patients with coronary artery disease] 73
Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry 73
Antithrombotic Therapy after TAVI: Evidence, Discordance, and Clinical Implications 73
Choice of access site and type of anticoagulant in acute coronary syndromes with advanced Killip class or out-of-hospital cardiac arrest 73
Von Willebrand Factor as a Novel Player in Valvular Heart Disease: From Bench to Valve Replacement 73
Improving adherence to Ticagrelor in patients after acute coronary syndrome: Results from the PROGRESS trial 72
Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and atrial thrombosis: An appraisal of current evidence 72
Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease 72
Prevalence and clinical significance of red flags in patients with hypertrophic cardiomyopathy 71
Immune-Checkpoint Inhibitor-Related Myocarditis: Where We Are and Where We Will Go 70
Role of dual lipid-lowering therapy in coronary atherosclerosis regression: Evidence from recent studies 70
Thrombus aspiration in hyperglycemic ST-elevation myocardial infarction (STEMI) patients: clinical outcomes at 1-year follow-up (vol 17, pg 512, 2018) 70
The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy 69
Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies 69
Impact of Clinical Presentation on Bleeding Risk after Percutaneous Coronary Intervention and Implications for the ARC-HBR Definition 68
P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials 68
New frontiers in antiplatelet therapy: guided therapy and de-escalation after acute coronary syndrome or percutaneous coronary intervention 67
[Gut microbiota and the cardiovascular system: current evidence and future perspectives] 67
von Willebrand Factor and Venous Thromboembolism: Pathogenic Link and Therapeutic Implications 66
Gender-related differences in changes of estimated bleeding risk in patients on dual antiplatelet therapy: the RE-SCORE multicenter prospective registry 65
Simulation Models of Therapy Intensification in Lipid-Lowering Medicine: Fact or Fantasy? 65
CYP2C19 Genotyping to Risk Stratify Patients After Coronary Stent Implantation: Time for a Personalized Approach? 65
ICARUS score for predicting peri-procedural bleeding in patients undergoing percutaneous coronary intervention with cangrelor 64
Epidemiology and Management of Patients With Acute Coronary Syndromes in Contemporary Real-World Practice: Evolving Trends From the EYESHOT Study to the START-ANTIPLATELET Registry 64
Low-Dose Ticagrelor in Patients With High Ischemic Risk and Previous Myocardial Infarction: A Multicenter Prospective Real-World Observational Study 64
P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events 63
Escalation and De-Escalation of Antiplatelet Therapy after Acute Coronary Syndrome or PCI: Available Evidence and Implications for Practice 63
Potential role of imaging markers in predicting future disease expression of arrhythmogenic cardiomyopathy 63
Use of bempedoic acid for LDL cholesterol lowering and cardiovascular risk reduction: a consensus document from the Italian study group on atherosclerosis, thrombosis and vascular biology 61
Inflammation in patients undergoing transcatheter aortic valve implantation: a therapeutic target for the future? 61
Optimizing Management of Stable Angina: A Patient-Centered Approach Integrating Revascularization, Medical Therapy, and Lifestyle Interventions 61
Letter by Calabrò et al Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)" 61
Do we need a redefinition of the cardiovascular risk categories used in the 2019 ESC/EAS guidelines on dyslipidaemias? 61
2024 ESC guidelines on chronic coronary syndromes: what is new in pharmacotherapy? 60
Letter by Calabro and Gragnano Regarding Article, "Dual Antiplatelet Therapy Continuation Beyond 1 Year After Drug-Eluting Stents: A Meta-Analysis of Randomized Trials" 60
In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study 60
P2Y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions 59
Left atrial and auricular thrombosis in patients with atrial fibrillation: from pathophysiology to treatment 59
Antithrombotic Therapy in Patients Taking Oral Anticoagulants and Undergoing Percutaneous Coronary Intervention: Time to Be Bold and Wise 59
ECG analysis in patients with acute coronary syndrome undergoing invasive management: rationale and design of the electrocardiography sub-study of the MATRIX trial 59
How has COVID-19 impacted the care of patients with acute coronary syndromes? 58
Visceral adipose tissue and residual cardiovascular risk: a pathological link and new therapeutic options 58
From Femoral to Radial Approach in Coronary Intervention: Review of the Literature and 6 Years Single-Center Experience 58
Dual Antiplatelet Therapy Duration in Conservatively Managed Patients with Acute Coronary Syndrome: Any News? 58
Perioperative care of cardiac patient’s candidate for non-cardiac surgery: a critical appraisal of emergent evidence and international guidelines 58
Cognitive Function in a Randomized Trial of Evolocumab 58
Methicillin-resistant staphylococcus aureus: Risk for general infection and endocarditis among athletes 58
Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: Per-Protocol Analysis of the GLOBAL LEADERS Trial 58
Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: Insight from SGLT2-I AMI PROTECT registry 57
Clinical significance of family history and bicuspid aortic valve in children and young adult patients with Marfan syndrome 57
Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients with ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial 57
Peripheral arterial disease has a strong impact on cardiovascular outcome in patients with acute coronary syndromes: from the START Antiplatelet registry 57
Prognostic implications of ischemia with nonobstructive coronary arteries (INOCA): Understanding risks for improving treatment 57
De-escalation strategies in patients with acute coronary syndrome: a step towards precision medicine 57
Discrepancies Between Physician-Perceived and Calculated Cardiovascular Risk in Primary Prevention: Implications for LDL-C Target Achievement and Appropriate Lipid-Lowering Therapy 56
Role of LipoprotEin(a) in CardiovascuLar diseases and premature acute coronary syndromes (RELACS study): Impact of Lipoprotein(a) levels on the premature coronary event and the severity of coronary artery disease 56
Multidisciplinary evaluation and management of obstructive hypertrophic cardiomyopathy in 2020: Towards the HCM Heart Team 56
Exercise, immune system, nutrition, respiratory and cardiovascular diseases during COVID-19: A complex combination 56
Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk 55
Impact of Regular Physical Activity on Aortic Diameter Progression in Paediatric Patients with Bicuspid Aortic Valve 55
Totale 7.409
Salva come PNG Salva come JPEG
Categoria #
all - tutte 50.415
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 50.415
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021196 0 0 0 0 0 2 61 11 19 13 62 28
2021/2022778 10 1 8 28 194 11 12 121 21 93 59 220
2022/20231.332 129 73 32 93 121 72 4 69 672 8 26 33
2023/2024734 44 21 22 37 191 108 54 6 6 33 54 158
2024/20252.890 7 28 8 77 452 383 357 237 403 463 280 195
2025/20264.924 458 679 657 587 954 1.589 0 0 0 0 0 0
Totale 11.312